Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response. Limits and monitoring Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 87, posted Aug 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response. Limits and monitoring Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 12, posted Aug 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The usual combination regimen can be used at CrCl above 30 mL/min. The renal section favors a loop diuretic in more severe impairment and discourages the fixed thiazide combination there. Limits and monitoring Evaluate volume status and renal function. Do not use single-ingredient irbesartan clearance data to dismiss the diuretic limitation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 24, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 15-60 mL/min, the label calls for no ivabradine dose change. Below 15, clinical data are unavailable. Limits and monitoring Follow the heart rate and indication-specific titration instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 33, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding No starting dose reduction is specified for ivosidenib with mild or moderate impairment and MDRD eGFR of at least 30 mL/min/1.73 m2. Limits and monitoring For severe impairment or dialysis, weigh potential benefit and risk individually. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 11, posted Dec 22, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Restriction or avoidance
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Advanced renal impairment contraindicates intranasal ketorolac. Limits and monitoring Check volume status, total duration of ketorolac therapy and other NSAID exposure. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 14, posted Dec 09, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding For HIV treatment in adults and adolescents at least 25 kg, reduce lamivudine dosing below CrCl 50 mL/min. At 30-49 mL/min give 150 mg daily; lower bands have distinct first and maintenance doses. Limits and monitoring Routine four-hour HD or peritoneal dialysis requires no additional dose. Use the HIV product's renal table, not the HBV product regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 24, posted Sep 14, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Select the initial lamotrigine schedule from the concomitant antiseizure regimen. Significant renal impairment may permit a lower maintenance dose. Limits and monitoring Verify the release form. Titration and restarting precautions remain essential because of serious rash risk. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 45, posted Aug 20, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Select the initial lamotrigine schedule from the concomitant antiseizure regimen. Significant renal impairment may permit a lower maintenance dose. Limits and monitoring Verify the release form. Titration and restarting precautions remain essential because of serious rash risk. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 44, posted Aug 20, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding No renal adjustment is specified from mild through severe impairment. Increased exposure in severe impairment may increase somnolence. Limits and monitoring Assess next-day impairment and other sedating medicines. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 39, posted Mar 03, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding Choose the starting dose from the Cockcroft-Gault CrCl table for the exact indication. Separate columns cover combination therapy, post-transplant maintenance or MDS, and follicular or marginal-zone lymphoma. Limits and monitoring Dialysis has a separate row with dosing after the session on dialysis days. Verify cycle days and blood counts before applying a schedule. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 41, posted Aug 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure CrCl normalized to 1.73 m2, mL/min/1.73 m2 Renal action or finding Adult immediate-release oral dosing uses CrCl adjusted to 1.73 m2. The dialysis row gives 500-1,000 mg every 24 hours and an additional 250-500 mg after dialysis. Limits and monitoring Use the labeled table for the other clearance bands. The XR and injection products have separate source records. Review 2 product or source cautions
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 36, posted Jan 29, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
